Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMP real-world study of luspatercept in Chinese beta-thalassemia
ChiCTR2300071687Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- May 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of luspatercept in beta thalassemia, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Change in transfusion burden from baseline to week 24. Planned start May 2023; status: not yet recruiting.
02
Drugs
luspatercept
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on ChiCTR2300071687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071687.